Terry MSc - G1 Therapeutics Chief Officer
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
Executive
Terry MSc is Chief Officer of G1 Therapeutics
| Age | 64 |
| Phone | 919 213 9835 |
| Web | https://www.g1therapeutics.com |
G1 Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.192) % which means that it has lost $0.192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0901) %, meaning that it created substantial loss on money invested by shareholders. G1 Therapeutics' management efficiency ratios could be used to measure how well G1 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.G1 Therapeutics currently holds 57.17 M in liabilities with Debt to Equity (D/E) ratio of 1.24, which is about average as compared to similar companies. G1 Therapeutics has a current ratio of 4.66, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about G1 Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dan Maziasz | Atara Biotherapeutics | N/A | |
| Amanda PharmD | Axsome Therapeutics | 41 | |
| Sr DO | Larimar Therapeutics | 63 | |
| Sunil PharmD | Annexon | N/A | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Holli Kolkey | Arcus Biosciences | N/A | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Ariel Hurley | Blueprint Medicines Corp | 50 | |
| Miriam Mason | Annexon | N/A | |
| Timothy Moore | Allogene Therapeutics | 63 | |
| Barbra Sasu | Allogene Therapeutics | N/A | |
| Spencer JD | PDS Biotechnology Corp | 54 | |
| Ryan Craig | Heron Therapeuti | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Shikhar MBA | Annexon | N/A | |
| William Grossman | Arcus Biosciences | 50 | |
| MRCP MD | Coherus BioSciences | 55 | |
| HenkAndre MD | Annexon | N/A | |
| Gary MD | Sana Biotechnology | N/A | |
| Pia Eaves | Arcus Biosciences | N/A | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 |
G1 Therapeutics Leadership Team
Elected by the shareholders, the G1 Therapeutics' board of directors comprises two types of representatives: G1 Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GTHX. The board's role is to monitor G1 Therapeutics' management team and ensure that shareholders' interests are well served. G1 Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, G1 Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Monica Thomas, General Officer | ||
| Jay Strum, Chief Scientific Officer | ||
| Andrew Perry, Chief Officer | ||
| Jeff Macdonald, Head of Investor Relations/Public Relations | ||
| Jennifer CPA, Chief Officer | ||
| Alexander MS, VP Operations | ||
| John V, Chief Officer | ||
| ChB MB, Chief RD | ||
| Terry MSc, Chief Officer | ||
| John Bailey, President CEO | ||
| William Roberts, Vice Communications | ||
| Mark Avagliano, Chief Officer | ||
| Evan MBA, Vice Marketing | ||
| Terry Murdock, Senior Vice President - Development Operations |
GTHX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is G1 Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.77) % | |||
| Operating Margin | (0.21) % | |||
| Current Valuation | 364.46 M | |||
| Shares Outstanding | 52.76 M | |||
| Shares Owned By Insiders | 10.92 % | |||
| Shares Owned By Institutions | 54.61 % | |||
| Number Of Shares Shorted | 3.41 M | |||
| Price To Earning | (1.95) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |